Ernexa Therapeutics Inc. Common Stock (ERNA)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I seek businesses with durable earnings, honest book value, and a margin of safety. Ernexa is a preclinical-stage company with five employees, no recent revenue in filed periods, and a history of losses. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported net income of -$4.0M and diluted EPS of -$3.40. In fiscal Q1 2026, the quarter ended 2026-03-31, net income was -$5.5M and diluted EPS -$6.95. For FY2025, the year ended 2025-12-31, net income was -$14.1M and diluted EPS -$2.24. FY2024, ended 2024-12-31, had revenue of $582,000 and a net loss of -$44.5M; FY2023, ended 2023-12-31, had revenue of $68,000 and a net loss of -$21.7M. That is not an earnings-producing business; it is a research project financed by capital markets. I see no evidence of a durable competitive moat. Its value depends on licenses and clinical success. Financial health is poor: trailing free cash flow is -$8.9M, and the FairStock-calculated FCF yield is -246.1% against a $3.6M market cap at the 2026-10-13 close. FairStock's P/E is -5.39, though negative earnings make it meaningless. FairStock's Piotroski score is 2/9 and Altman Z is -56.72. Debt-to-equity of 0.11 is a minor positive, and FairStock's P/B of 0.81 at that close means the price is below reported book value. But book value is likely cash being consumed, not productive assets. FairStock's ROE is -320.72% and ROCE is -105.56%. The $2.21 price sits between a 52-week low of $0.18 and high of $15.88; beta is 2.62. FairStock score is 68/100, but the Lynch category is none because of four straight loss years. Without profits, valuation is a speculative option on data. I would wait for evidence.

In plain English: Ernexa Therapeutics is a very small, five-employee biotech working on stem-cell treatments for cancer and autoimmune disease. Its therapies are still in early research, it has no meaningful recent sales, and it keeps losing money. At $2.21, the price looks low compared with the company's reported assets minus debts, but the losses and cash burn make that cheapness uncertain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer